| abstract |
The present invention relates to the field of infection and inflammation and, more specifically, to the field of pathogen-induced nuclear factor kappa B activation. More specifically, a novel splice variant of MyD88, (MyD88 S ), which has been identified encoding a protein that inhibits LPS-induced NF-κB activation. MyD88 S is a target to inhibit the phenomenon of endotoxin-tolerance that occurs in sepsis. |